Citadel Advisors
MRVI icon

Citadel Advisors’s Maravai LifeSciences MRVI Stock Holding History

Citadel Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Sell
39,200
-8,700
-18% -$37.6K ﹤0.01% 11590
2026
Q1 		$136K Buy
47,900
+35,200
+277% +$119K ﹤0.01% 11772
2025
Q4 		$41.3K Buy
12,700
+1,100
+9% +$3.7K ﹤0.01% 12124
2025
Q3 		$33.3K Sell
11,600
-900
-7% -$2.3K ﹤0.01% 12371
2025
Q2 		$30.1K Sell
12,500
-200
-2% -$420 ﹤0.01% 11974
2025
Q1 		$28.1K Sell
12,700
-7,400
-37% -$29.2K ﹤0.01% 12881
2024
Q4 		$110K Buy
20,100
+14,800
+279% +$95.2K ﹤0.01% 11352
2024
Q3 		$44K Buy
5,300
+3,100
+141% +$26.8K ﹤0.01% 12051
2024
Q2 		$15.8K Sell
2,200
-20,400
-90% -$176K ﹤0.01% 12818
2024
Q1 		$196K Buy
22,600
+22,100
+4,420% +$150K ﹤0.01% 10349
2023
Q4 		$3.27K Sell
500
-2,400
-83% -$15.5K ﹤0.01% 13613
2023
Q3 		$29K Sell
2,900
-2,200
-43% -$24.2K ﹤0.01% 12298
2023
Q2 		$63.4K Buy
5,100
+1,500
+42% +$20.2K ﹤0.01% 11524
2023
Q1 		$50.4K Sell
3,600
-13,100
-78% -$188K ﹤0.01% 12130
2022
Q4 		$239K Sell
16,700
-3,100
-16% -$48.8K ﹤0.01% 9788
2022
Q3 		$505K Sell
19,800
-9,700
-33% -$243K ﹤0.01% 8432
2022
Q2 		$838K Buy
29,500
+1,500
+5% +$47.5K ﹤0.01% 7444
2022
Q1 		$988K Sell
28,000
-400
-1% -$13.4K ﹤0.01% 7714
2021
Q4 		$1.19M Sell
28,400
-37,500
-57% -$1.52M ﹤0.01% 7519
2021
Q3 		$3.23M Buy
65,900
+21,100
+47% +$1.03M ﹤0.01% 5196
2021
Q2 		$1.87M Buy
44,800
+16,800
+60% +$651K ﹤0.01% 6778
2021
Q1 		$998K Buy
+28,000
New +$928K ﹤0.01% 8113

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Citadel Advisors's MRVI Position: Q2 2026 in Review

Citadel Advisors increased its Maravai LifeSciences (MRVI) stake by 43% in Q2 2026, buying an estimated $2.76M and bringing the position to 2,122,598 shares worth $13.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3145.

Citadel Advisors first reported a position in MRVI in Q4 2020 and has held it in 22 quarters since. The position peaked at $64.7M in Q3 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Citadel Advisors held 2,122,598 shares of Maravai LifeSciences worth $13.2M as of Q2 2026.
  • Citadel Advisors bought 638,279 Maravai LifeSciences shares in Q2 2026, an estimated $2.76M.
  • Maravai LifeSciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3145 holding.
  • Citadel Advisors first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Maravai LifeSciences position peaked at $64.7M in Q3 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.